Literature DB >> 24346905

Pyoderma gangrenosum with renal and splenic impairment--case report.

Luciana Rabelo de Carvalho1, Virgínia Vinha Zanuncio1, Bernardo Gontijo2.   

Abstract

Pyoderma gangrenosum is an uncommon and recurrent neutrophilic dermatosis of unknown cause. The lesions usually start as tender sterile papulopustules or erythematous nodules that undergo necrosis followed by ulceration. The lower limbs are most commonly affected and around half of the cases are associated with systemic disorders. Although rare, cases of pyoderma gangrenosum with extramucocutaneous sterile neutrophilic infiltrate have been reported, with the lungs being the most commonly affected organ. We report a case of pyoderma gangrenosum with splenic and renal impairment. Pyoderma gangrenosum should be considered a multisystemic disease with classic cutaneous manifestations and potential involvement of internal organs.

Entities:  

Mesh:

Year:  2013        PMID: 24346905      PMCID: PMC3876020          DOI: 10.1590/abd1806-4841.20132448

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  10 in total

Review 1.  Pyoderma gangrenosum.

Authors:  J P Callen
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

2.  Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia.

Authors:  M Vadillo; A Jucgla; D Podzamczer; G Rufi; A Domingo
Journal:  Br J Dermatol       Date:  1999-09       Impact factor: 9.302

Review 3.  Pyoderma gangrenosum: classification and management.

Authors:  F C Powell; W P Su; H O Perry
Journal:  J Am Acad Dermatol       Date:  1996-03       Impact factor: 11.527

4.  Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients.

Authors:  A M Binus; A A Qureshi; V W Li; L S Winterfield
Journal:  Br J Dermatol       Date:  2011-12       Impact factor: 9.302

5.  [Cutaneous, mucosal and systemic pyoderma gangrenosum].

Authors:  C Poiraud; V Gagey-Caron; S Barbarot; C Durant; S Ayari; J-F Stalder
Journal:  Ann Dermatol Venereol       Date:  2010-02-18       Impact factor: 0.777

6.  Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: a rarely recognized extracutaneous manifestation of a neutrophilic dermatosis.

Authors:  T S Brown; G S Marshall; J P Callen
Journal:  J Am Acad Dermatol       Date:  2000-07       Impact factor: 11.527

7.  [Pyoderma gangrenosum with aseptic spleen abscess].

Authors:  N Brahimi; E Maubec; O Boccara; E Marinho; L Valeyrie-Allanore; C Lecaille; V Sebban; B Hersent; C Picard-Dahan; V Descamps; B Crickx
Journal:  Ann Dermatol Venereol       Date:  2008-12-09       Impact factor: 0.777

Review 8.  Pyoderma gangrenosum: a review.

Authors:  A Neil Crowson; Martin C Mihm; Cynthia Magro
Journal:  J Cutan Pathol       Date:  2003-02       Impact factor: 1.587

9.  Pyoderma gangrenosum: a review of 86 patients.

Authors:  F C Powell; A L Schroeter; W P Su; H O Perry
Journal:  Q J Med       Date:  1985-05

10.  Multiple cavitary pulmonary nodules in association with pyoderma gangrenosum: case report.

Authors:  Maraya de Jesus Semblano Bittencourt; Luciana Fontenele Brito Soares; Lilia Sampaio Lobato; Alexandre Dias Mançano; Helandro Stuart Castro Leandro; Diana Mendes da Fonseca
Journal:  An Bras Dermatol       Date:  2012 Mar-Apr       Impact factor: 1.896

  10 in total
  3 in total

1.  Pyoderma gangrenosum with spleen involvement. Review of the literature and case report.

Authors:  Rodica Cosgarea; Simona Corina Senilă; Radu Badea; Loredana Ungureanu
Journal:  J Dermatol Case Rep       Date:  2016-11-13

2.  Pyoderma Gangrenosum with Splenic Abscess- A Rare Association.

Authors:  Aditi Bansal; Ankur Singla; Aminder Singh; Sukhjot Kaur
Journal:  Indian Dermatol Online J       Date:  2022-03-03

3.  Chronic renal comorbidities in pyoderma gangrenosum: a retrospective cohort study.

Authors:  Khalaf Kridin; Arieh Solomon; Rimma Laufer Britva; Dana Tzur Bitan; Arnon D Cohen
Journal:  Immunol Res       Date:  2021-04-22       Impact factor: 2.829

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.